摘要
目的探究免疫治疗联合化疗治疗程序性死亡受体配体1(PD-L1)高表达晚期非小细胞肺癌的疗效。方法回顾性抽取安康市中心医院2020年1月至2022年12月收治的PD-L1高表达晚期非小细胞肺癌患者76例,按照随机数字表法分为对照组和观察组,每组38例。对照组接受单纯化疗,观察组接受免疫治疗联合化疗治疗,比较两组临床疗效,血清癌胚抗原(CEA)、磷状细胞癌相关抗原(SCC-Ag)、细胞角蛋白19血清片段21-1(CYFRA21-1)水平及远期生存情况。结果观察组治疗总有效率(63.16%,24/38)高于对照组(39.47%,15/38),P<0.05。治疗后,观察组CEA、SCC-Ag、CYFRA21-1水平低于对照组(P<0.05)。观察组中位生存时间[(12.26±3.26)个月]长于对照组[(8.59±1.26)个月],P<0.05。结论免疫治疗联合化疗治疗PD-L1高表达晚期非小细胞肺癌中能获取满意成效,能进一步控制病灶进展,且降低肿瘤标志物水平,延长患者生存期。
Objective To investigate the efficacy of immunotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer with high expression of programmed death receptor ligand 1(PD-L1).Methods A total of 76 patients with advanced non-small cell lung cancer with high expression of PD-L1 treated in Ankang Central Hospital from January 2020 to December 2022 were retrospectively selected.And they were divided into the control group and the observation group by random number table method,with 38 cases in each group.The control group was treated by chemotherapy alone,while the observation group was treated by immunotherapy combined with chemotherapy.The clinical efficacy,serum levels of carcinoembryonic antigen(CEA),squamous cell carcinoma associated antigen(SCC-Ag)and cytokeratin 19 serum fragment 21-1(CYFRA21-1),and long-term survival were compared between the two groups.Results The total effective rate of the observation group(63.16%,24/38)was higher than that of the control group(39.47%,15/38),P<0.05.After treatment,the levels of CEA,SCC-Ag,and CYFRA21-1 in the observation group were lower than those in the control group(P<0.05).The median survival time of the observation group was(12.26±3.26)months,longer than the(8.59±1.26)months of the control group(P<0.05).Conclusions Immunotherapy combined with chemotherapy can achieve ideal results in the treatment of advanced non-small cell lung cancer with high expression of PD-L1;this treatment protocol can further control the progression of lesions,reduce the level of tumor markers,and prolong the survival of patients.
作者
邓迎丽
崔杰
Deng Yingli;Cui Jie(Department of Respiratory MedicineⅡ,Ankang Central Hospital,Ankang 725000,China;Department of Oncology,Ankang Central Hospital,Ankang 725000,China)
出处
《中国实用医刊》
2024年第5期5-7,共3页
Chinese Journal of Practical Medicine
关键词
免疫治疗
化疗
程序性死亡受体配体1
晚期非小细胞肺癌
Immunotherapy
Chemotherapy
Programmed death receptor ligand 1
Advanced non-small cell lung cancer
作者简介
通信作者:邓迎丽,Email:hua635625600@126.com。
